Clinical Trial Update: A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density. [Phase 3]

View source ↗

Summary

A Phase 3 randomized, double-blind trial comparing denosumab with alendronate in postmenopausal women with low bone mineral density completed, and results were …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteopenia
• Osteoporosis

Drugs mentioned

• FOSAMAX (ALENDRONATE SODIUM)
• Prolia (denosumab)

Snippet

Sponsor: Amgen | Conditions: Osteoporosis, Osteopenia | Phase 3 | Status: COMPLETED | Results posted: 2010-07-19